TGF-ß2 was first described in human glioblastoma cells. It was found that TGF-ß2 is capable of suppressing interleukin-2-dependent growth of T lymphocytes. Thereby, it was named glioblastoma-derived T cell suppressor factor (G-TsF). Physiologically, TGF-ß2 is expressed by neurons and astroglial cells in embryonic nervous system [17]. It is also important in tumor growth enhancing cell proliferation in an autocrine way and/or reducing immune-surveillance of tumor development [18].